Skip to main content

Money

Markets, macro, banking, investment funds, and insurance developments.

Money

Briefing: The Best ETF Over The Past 10 Years Turned $10,000 To $65,100

Strategic angle: Discover the top-performing ETF that significantly increased investment returns over the last decade.

Money

Briefing: This REIT Offers An Eye-Catching Yield With Stable Growth

Strategic angle: This REIT Offers An Eye-Catching Yield With Stable Growth

Money

Briefing: The Iran war is ‘bad for stocks’ — rich young Americans have already ditched stocks for alternative assets. Should you?

Strategic angle: As the Iran war impacts the stock market, affluent young investors are turning to alternative assets. Explore whether you should follow suit.

Money

Briefing: US inflation will surge to 4.2% on energy shock, warns OECD

Strategic angle: Middle East war to push American price growth to ‘highest in G7’

Money

Briefing: Barry Bonds shares how close he was to signing with Yankees

Strategic angle: MLB's home run king explained how he ultimately landed with the Giants instead of the Yankees ahead of the 1993 season.

Money

Briefing: Jim Cramer says Wall Street is in denial about the market

Strategic angle: Wall Street is in denial about the market's strength, Jim Cramer said, arguing that investors are dismissing falling oil prices and the 'presidential Put.'

Money

Briefing: Birthright citizenship: more on Pete Patterson’s claims

Strategic angle: Attorney Pete Patterson’s latest post on birthright citizenship repeats significant errors and introduces new misconceptions.

Money

Briefing: Significant grade inflation may be occurring in graduate education, according to decades' worth of data

Strategic angle: Analysis of two decades of student data at a large U.S. university suggests that grade inflation exists in graduate education.

Money

Briefing: Will Vanguard Growth Keep Crushing Its ETF Peers?

Strategic angle: An analysis of Vanguard Growth's performance against other ETFs.

Money

Briefing: Is It Too Late To Consider USA Rare Earth (USAR) After A 147% One-Year Surge?

Strategic angle: An analysis of USA Rare Earth's significant stock surge and its implications for investors.

Money

Briefing: Here’s Why Meta Platforms (META) is a Key Stock in Jim Cramer’s Latest Portfolio

Strategic angle: Meta Platforms is highlighted as a significant investment choice by Jim Cramer.

Money

Briefing: Apple (AAPL) Rose on Better-Than-Feared iPhone 17 Sales

Strategic angle: Apple's stock performance improved due to stronger-than-expected sales of the iPhone 17.

Money

Briefing: Famed Lille bakery shares story behind its 'gaufres' on International Waffle Day

Strategic angle: This Wednesday is International Waffle Day – a celebration for waffle lovers everywhere, particularly in France.

Money

Briefing: These Car Brands Aren't Making It Through The Next Recession

Strategic angle: A look at the car brands that may struggle to survive the upcoming economic downturn.

Money

Better Nuclear Energy Stock: Cameco (CCJ) vs. Centrus Energy (LEU)

A comparison of two leading nuclear energy stocks, Cameco and Centrus Energy.

Money

Briefing: New NMR Method Allows the Observation of Chalcogen Bonds

Strategic angle: A breakthrough in NMR technology enables scientists to study chalcogen bonds, which play a crucial role in biological processes.

Money

Briefing: French economic growth undercut by war in Iran, national statistics office says

Strategic angle: The French economy will grow by only 0.2% in the first half of the year instead of the 0.3% forecast, according to Insee.

Money

Briefing: Got $2,000? 2 Top Growth Stocks to Buy That Could Double Your Money.

Strategic angle: Discover two promising growth stocks that could significantly increase your investment.

Money

Briefing: Micron Stock Falls As Rival SK Hynix Ups Investments

Strategic angle: Micron faces challenges as SK Hynix increases its market investments.

Money

Briefing: FDA slams Soon-Shiong and ImmunityBio for making ‘false and misleading’ claims about a drug

Strategic angle: Patrick Soon-Shiong, a controversial figure in the biotech industry, was accused by the FDA of making false and misleading claims about a cancer treatment.